Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
Often when using nanoparticles to target and penetrate cancer cells, the shape of the tiny drug-carrying vehicles is crucial to their performance. Researchers have now found evidence that "worm-shaped" nanoparticles may be more effective than spheres at delivering cancer drugs to breast cancer.
It looks like BioDelivery Sciences is on its way to a Phase III clinical trial of its topical gel treatment for painful diabetic neuropathy following a "positive" meeting with the FDA.
Tiny, programmed drug-delivery vehicles called nanorobots have the potential to bring about more targeted treatments with fewer side effects. And a research team has built the beginnings of a DNA-based cage capable of holding and releasing drugs in such a programmed way.
At the Georgia Institute of Technology and Emory University, researchers are looking for a new way to treat rotator cuff injuries, a common baseball shoulder ailment that has ended many a star pitcher's career.
The co-founders of Bind Therapeutics, which includes MIT professor and entrepreneur Robert Langer, published new data for its targeted nanoparticle platform called Accurins, which are designed to carry drugs to specific parts of the body to treat diseases.
After earlier this month announcing promising new data supporting its genetic treatment for hepatitis B, Arrowhead Research is moving forward with the candidate, submitting its application to begin a Phase IIa trial of ARC-520, which uses its polymer-based method to effectively deliver RNAi to the nucleus.
Focal Therapeutics is working to address the idea of targeted breast cancer therapy in a way that drug companies don't. The California outfit markets a 3-D tissue marker designed to help surgeons spot the precise site for tumor removal and subsequent delivery of radiation treatment.
Aptar Pharma has taken a major leap beyond spray pumps and inhalers. At a major November conference, it debuted prefilled, auto-injectable drug delivery technology designed to help it attract more biopharmaceutical clients.
Gene-silencing expert Alnylam is $7 million richer thanks to some positive mid-stage results for its Genzyme-licensed RNA-interference candidate, and the Cambridge, MA, company is looking to be the first to market with the difficult-to-deliver class of treatments.
Naturally occurring cell materials called bionanocomposites could hold clues to the creation of hybrid natural-synthetic drug delivery systems with high degrees of biodegradability. And researchers from the Polytechnic Institute of New York have found key components of these nanomaterials that could help pave the way to that point.
Researchers in Finland have come up with a new application for well-known materials known as bisphosphonates that includes a possible role for drug delivery.
Unilife took another big step this week, signing a long-term contract agreement with generics maker Hikma Pharmaceuticals to use Unilife's injectable technology and netting up to $40 million in the process.
Actinium Pharmaceuticals spoke with the FDA last week and is now planning to roll out a Phase III pivotal trial of its targeted immunotherapeutic cancer treatment using its radioisotope delivery platform.
New Jersey device outfit Svelte Medical Systems finished enrolling patients in a pivotal study of its Integrated Delivery System (IDS) drug-eluting coronary stent, comparing it with Medtronic's Resolute Integrity drug-eluting stent.
Researchers at the Icahn School of Medicine at Mount Sinai Hospital used a virus to deliver genes directly to the heart to reverse heart failure, shrinking an enlarged heart and improving its function.
To get through a dense jungle, you'll need to clear a path. Similarly, to get past a thick network of scaffolding that often prevents drugs from reaching cancer cells, UCLA researchers have developed nanoparticles capable of clearing a path for drugs to pass through to a tumor.
FierceDrugDelivery spoke with the prolific drug delivery expert about the field's future, regarding nanotechnology in particular, as well as some of the projects Langer's lab and various business ventures are undertaking currently to make next-gen nanomedicine a reality.
Israel's Oramed won a patent from the European Union for its oral insulin pill, giving the Jerusalem company a potential foothold in the diabetes market estimated to be worth about $14 billion by 2017, according to analysts.
A team of researchers from Nottingham University in the U.K. have repurposed a bone-healing polymer to achieve something very different: delivery of cancer drugs to tumors in the brain after surgery.